series-b
Stage
2
Investors
About
Develops a programmable gene silencing platform for cell and gene therapies that controls gene expression in response to cell identity and cellular state, enabling disease‑responsive and tunable therapeutic activity.
Explore Laverock Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.